Dendritic Cell-Targeted mRNA Vaccines
Quick Facts
What are dendritic cells and why target them with an mRNA vaccine?
Dendritic cells sit at the interface between innate and adaptive immunity. They capture fragments of pathogens or abnormal cells, process them into small peptides, and present those peptides to naive T cells in lymph nodes. Together with co-stimulatory signals and cytokines, this presentation determines whether T cells become cytotoxic killers, helper cells, or long-lived memory cells.
Standard mRNA vaccines are packaged in lipid nanoparticles that are taken up by many cell types, including muscle cells and various immune cells. Dendritic cell-targeted designs try to improve on this by altering the delivery particle, for example with surface ligands, so that more of the mRNA reaches antigen-presenting cells. In principle, this could allow lower doses, more consistent antigen presentation and a response skewed toward T cells rather than antibodies alone. These strategies are an active area of research, and most are not yet proven in large human trials.
Why does tuberculosis need a vaccine that builds T-cell immunity?
The World Health Organization estimates that around 10.8 million people developed tuberculosis in 2023, and about 1.25 million died from the disease, making it one of the leading infectious causes of death worldwide. BCG, first used in humans in the 1920s, offers reasonable protection against severe forms of TB in young children, but its protection against pulmonary TB in adolescents and adults is variable and often limited.
Because the bacterium lives inside macrophages, antibodies alone are generally not enough to clear it. CD4 and CD8 T cells, and the cytokines they release, such as interferon-gamma, are considered central to containing infection. That is why vaccine developers are interested in platforms that can efficiently prime T cells. Other candidates are further along; for example, the M72/AS01E subunit vaccine has been in a large phase 3 trial. mRNA-based approaches that target dendritic cells are earlier in development, and it is not yet known whether they will outperform existing strategies.
What hurdles remain before targeted mRNA vaccines reach patients?
A first-in-human study of any new platform primarily asks whether the vaccine is safe and whether it provokes the intended immune response. Researchers will look at reactogenicity, such as injection-site reactions and fever, and measure the size, type and persistence of T-cell responses. Positive early immune data are encouraging but do not guarantee clinical protection, a lesson learned repeatedly in TB vaccine research.
Practical questions also matter. TB burden is highest in low- and middle-income countries, so any successful vaccine will need to be affordable, stable outside ultra-cold storage if possible, and easy to scale. Efficacy trials are also lengthy because TB develops slowly and only a fraction of infected people become ill. Funding from philanthropic and public sources is often what allows such early programs to progress, but patients should not expect a new TB vaccine in the near term.
Frequently Asked Questions
No. No mRNA vaccine for tuberculosis is approved. Candidates are in preclinical or early clinical development, and BCG remains the only licensed TB vaccine.
A dendritic cell is an antigen-presenting immune cell that captures foreign material and shows fragments of it to T cells, helping to start and shape an adaptive immune response.
Not necessarily. Early trials mainly assess safety and immune responses. Protection against disease has to be shown in larger efficacy trials, which are especially challenging for tuberculosis.
References
- World Health Organization. Global Tuberculosis Report 2024.
- PR Newswire. Akagera Medicines Receives $7.8 Million Grant Expansion to Advance Dendritic Cell-Targeted mRNA Tuberculosis Vaccine Toward First-in-Human Trial. 2026.
- World Health Organization. Tuberculosis fact sheet.